LIWANLI Innovation Co., Ltd. (3054.TW)
TWD 23.5
(1.29%)
TWD 23.5
(1.29%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 38.88 Million TWD | 14.41% |
| 2022 | 33.98 Million TWD | -28.91% |
| 2021 | 47.81 Million TWD | -82.73% |
| 2020 | 276.87 Million TWD | 113.34% |
| 2019 | 129.78 Million TWD | -30.04% |
| 2018 | 185.51 Million TWD | -46.72% |
| 2017 | 348.21 Million TWD | 7.77% |
| 2016 | 323.09 Million TWD | -61.3% |
| 2015 | 834.9 Million TWD | -62.66% |
| 2014 | 2.23 Billion TWD | -8.5% |
| 2013 | 2.44 Billion TWD | -10.7% |
| 2012 | 2.73 Billion TWD | 18.1% |
| 2011 | 2.31 Billion TWD | 127.37% |
| 2010 | 1.01 Billion TWD | -18.02% |
| 2009 | 1.24 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 23.53 Million TWD | 1.09% |
| 2024 Q2 | 23.28 Million TWD | -33.57% |
| 2024 Q1 | 35.05 Million TWD | 148.99% |
| 2023 Q3 | 7.1 Million TWD | -30.39% |
| 2023 Q2 | 10.2 Million TWD | 36.21% |
| 2023 Q1 | 7.49 Million TWD | -26.34% |
| 2023 FY | 38.88 Million TWD | 14.41% |
| 2023 Q4 | 14.07 Million TWD | 98.1% |
| 2022 Q2 | 7.67 Million TWD | -6.98% |
| 2022 FY | 33.98 Million TWD | -28.91% |
| 2022 Q4 | 10.17 Million TWD | 29.01% |
| 2022 Q1 | 8.25 Million TWD | -20.58% |
| 2022 Q3 | 7.88 Million TWD | 2.76% |
| 2021 FY | 47.81 Million TWD | -82.73% |
| 2021 Q1 | 13.55 Million TWD | -40.95% |
| 2021 Q2 | 15.99 Million TWD | 18.02% |
| 2021 Q3 | 7.88 Million TWD | -50.73% |
| 2021 Q4 | 10.38 Million TWD | 31.84% |
| 2020 Q2 | 102.62 Million TWD | 0.22% |
| 2020 Q1 | 102.4 Million TWD | 122.69% |
| 2020 FY | 276.87 Million TWD | 113.34% |
| 2020 Q4 | 22.94 Million TWD | -53.08% |
| 2020 Q3 | 48.9 Million TWD | -52.34% |
| 2019 FY | 129.78 Million TWD | -30.04% |
| 2019 Q2 | 18.71 Million TWD | -22.59% |
| 2019 Q3 | 40.91 Million TWD | 118.62% |
| 2019 Q1 | 24.17 Million TWD | -50.01% |
| 2019 Q4 | 45.98 Million TWD | 12.4% |
| 2018 Q3 | 37.01 Million TWD | -23.38% |
| 2018 Q2 | 48.3 Million TWD | -6.78% |
| 2018 Q4 | 48.36 Million TWD | 30.66% |
| 2018 FY | 185.51 Million TWD | -46.72% |
| 2018 Q1 | 51.82 Million TWD | -34.27% |
| 2017 Q4 | 78.84 Million TWD | -20.17% |
| 2017 Q1 | 103.99 Million TWD | -37.19% |
| 2017 Q2 | 66.58 Million TWD | -35.97% |
| 2017 Q3 | 98.77 Million TWD | 48.34% |
| 2017 FY | 348.21 Million TWD | 7.77% |
| 2016 Q4 | 165.58 Million TWD | 80.46% |
| 2016 Q1 | 39.91 Million TWD | -63.36% |
| 2016 FY | 323.09 Million TWD | -61.3% |
| 2016 Q2 | 25.84 Million TWD | -35.25% |
| 2016 Q3 | 91.75 Million TWD | 255.07% |
| 2015 Q1 | 352.32 Million TWD | -7.69% |
| 2015 FY | 834.9 Million TWD | -62.66% |
| 2015 Q4 | 108.91 Million TWD | -30.82% |
| 2015 Q3 | 157.43 Million TWD | -27.19% |
| 2015 Q2 | 216.22 Million TWD | -38.63% |
| 2014 Q4 | 381.69 Million TWD | -6.2% |
| 2014 FY | 2.23 Billion TWD | -8.5% |
| 2014 Q1 | 741.83 Million TWD | 20.31% |
| 2014 Q2 | 705.48 Million TWD | -4.9% |
| 2014 Q3 | 406.91 Million TWD | -42.32% |
| 2013 Q4 | 616.58 Million TWD | 31.71% |
| 2013 FY | 2.44 Billion TWD | -10.7% |
| 2013 Q1 | 686.01 Million TWD | 30.57% |
| 2013 Q2 | 672.94 Million TWD | -1.9% |
| 2013 Q3 | 468.14 Million TWD | -30.43% |
| 2012 Q3 | 635.19 Million TWD | -23.5% |
| 2012 Q1 | 745.67 Million TWD | -26.92% |
| 2012 FY | 2.73 Billion TWD | 18.1% |
| 2012 Q4 | 525.41 Million TWD | -17.28% |
| 2012 Q2 | 830.27 Million TWD | 11.34% |
| 2011 Q2 | 250.44 Million TWD | -21.12% |
| 2011 Q3 | 728.88 Million TWD | 191.04% |
| 2011 Q4 | 1.02 Billion TWD | 40.0% |
| 2011 FY | 2.31 Billion TWD | 127.37% |
| 2011 Q1 | 317.49 Million TWD | 1.56% |
| 2010 Q2 | 234.82 Million TWD | 14.29% |
| 2010 FY | 1.01 Billion TWD | -18.02% |
| 2010 Q3 | 266.24 Million TWD | 13.38% |
| 2010 Q1 | 205.46 Million TWD | 0.0% |
| 2010 Q4 | 312.62 Million TWD | 17.42% |
| 2009 FY | 1.24 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Grape King Bio Ltd | 10.63 Billion TWD | 99.634% |
| Standard Chem & Pharm CO., LTD. | 6.23 Billion TWD | 99.377% |
| Maywufa Company Ltd. | 1.3 Billion TWD | 97.01% |
| ScinoPharm Taiwan, Ltd. | 3.18 Billion TWD | 98.779% |
| Lotus Pharmaceutical Co., Ltd. | 16.95 Billion TWD | 99.771% |
| YungShin Global Holding Corporation | 7.02 Billion TWD | 99.447% |
| PhytoHealth Corporation | 162.48 Million TWD | 76.068% |
| SCI Pharmtech, Inc. | 1.2 Billion TWD | 96.771% |
| Formosa Laboratories, Inc. | 4.36 Billion TWD | 99.108% |
| PharmaEssentia Corporation | 5.1 Billion TWD | 99.238% |
| Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | 99.726% |